IGF-I binds to its receptor (IGF-1R) and activates downstream signaling pathways such as PI3K/AKT and MAPK, promoting cell proliferation and inhibiting apoptosis, thereby driving the development and progression of solid tumors such as prostate cancer. Here, IGF1 is linked to prostate carcinoma.